A combination of herbal extracts and a probiotic supplement and formulated as a dietary supplement helps mitigate symptoms of bronchopulmonary disease in conjunction with the anti-inflammatory mechanisms of the probiotics. Provided are embodiments of a probiotic nutraceutical composition that delivers 3 strains of Lactobacillus spp. to the gut lining of human subjects to reduce neutrophilic inflammation as a result of or causative agent of bronchopulmonary disease. In addition to the three Lactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.
A surgical tool support system is provided. The system includes a support portion, a swivel arm, and a tool holder for holding a surgical tool coupled to a distal end of the swivel arm. The tool holder can have a locking joint controlled by an actuator such that the tool holder can be locked into a position along multiple axes of rotation. The system can offset the force required by a user to move the surgical tool, thereby reducing fatigue.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Suto, Mark J.
Mathew, Bini
Agarwal, Anupam
Traylor, Amie M.
Abrégé
The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
King, Peter
Nabors, Louis B.
Filippova, Natalia
Yang, Xiuhua
Ananthan, Subramaniam
Pathak, Vibha
Abrégé
This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.
A urine collection device is provided. The urine collection device includes a basin configured to fit a perineal region of a female human subject and to receive urine; a lip attached to the basin and having a contact surface for attachment to the perineal region; a ridge extending into the basin and disposed along an inferior portion of the lip to prevent leakage of urine from the basin; and a drain opening in the basin for draining the urine. The urine collection device advantageously prevents leakage and allows for easy access for urine analysis and measurement of urine output. Methods and systems for collecting and quantifying urine are also provided.
The present technology relates to methods comprising the administration of methotrexate and glucarpidase to treat central nervous system lymphoma in a subject in need thereof. Kits for use in practicing the methods are also provided.
A number of MS- and natural-saponin-based vaccine adjuvant candidates have been prepared. The MS derivatives were prepared by incorporating a terminal-functionalized side chain into the C3 glucuronic acid unit of the natural saponins MS I and II through amide formation reaction; and the QS analogs were prepared via multi-step organic synthesis. These unnatural saponins showed significantly different immunostimulant activity profiles, suggesting that the structure of side chain, triterpenoid core, and oligosaccharide domain together orchestrate each saponin's characteristic potentiation of immune responses.
C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A method is provided for increasing the sensitivity of the complement-dependent cellular cytoxicity analysis that establishes whether a potential transplant recipient patient expresses donor organ-reactive antibodies that would reduce or prevent acceptance of the donor organ by a recipient. At least one gene encoding a complement inhibitor is inactivated in cells derived from a candidate transplant organ. Such modified cells, because they no longer produce at least one complement inhibitor, when placed in a serum sample from a potential transplant recipient, do not reduce the effective activity of serum complement. A lower level of recipient patient serum antibodies becomes effective in inducing detectable lysis of the donor cells.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
10.
METHODS FOR CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS
This invention includes methods for assessing and treating risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, for example rheumatoid arthritis (RA). Provided are methods for assessing risk, for recommending therapy, for prognosis and monitoring, and for treatment, which are advantageously accurate for CVD in RA. The methods include measuring quantitative data for biomarkers, calculating a CVD risk score for a subject using training data, and validating the CVD risk score with a set of validation clinical data.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A lottery ticket dispensing system includes a cabinet housing and a lottery ticket array insertable into the cabinet housing. The array includes a plurality of individual bins in a stacked configuration. A dispensing unit is inserted into each of the bins and an automatic separation module in which a leading ticket of a continuous strip of lottery tickets is automatically separated and dispensed from the bin. The lottery ticket array is insertable into and removable from the cabinet housing as a single unit. A stacked configuration of the bins has opposite sides defined by the sides of the bins. At least one first component of a detachable support system is attached to the opposite sides of the stacked configuration, the first component cooperating with a second component of the detachable support system provided on inner side walls of the cabinet housing.
An electrode system for use in an AC-electrospinning process comprises an electrical charging component electrode and at least one of an AC field attenuating component and a precursor liquid attenuating component. The electrical charging component electrode is electrically coupled to an AC source that places a predetermined AC voltage on the electrical charging component electrode. In cases in which the electrode system includes the AC field attenuating component, it attenuates the AC field generated by the electrical charging component electrode to better shape and control the direction of the fibrous flow. In cases in which the electrode system includes the precursor liquid attenuating component, it serves to increase fiber generation, even if the top surface of the liquid precursor is not ideally shaped or is below a rim or lip of the reservoir that contains the liquid on the electrical charging component electrode.
The invention provides combination therapies for treating cancer comprising compositions and methods for ?d T cell immunotherapy in combination DDR inhibitors, including but not limited to PARP inhibitors. Preferably, the combination of ?d T cell immunotherapy and PARP inhibitors for the treatment of cancer further includes combinations with other immunotherapies such as immune checkpoint (ICP) blockade therapy and/or DNA damaging agents such as cytotoxic chemotherapeutic agents. Preferably, when the combination of ?d T cell immunotherapy and DDR inhibitor therapy further include chemotherapeutic agents, the ?d T cells are genetically modified to impart resistance to that chemotherapeutic agent.
The present invention provides an attenuated Old World alphavirus particle and methods of making same and using same as a vaccine and in gene therapy and immunotherapy methods.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
15.
IDENTIFYING COMPOUNDS FOR TREATING CANCER AND USE THEREOF
Provided herein is a method for identifying compounds that inhibit cell growth or have cytotoxic activity against cancer cells, such as hematological cancer cells or ovarian cancer cells, in a subject. Further provided is a method for identifying one or more compounds that sensitize refractory cancer cells from a subject. Also provided are compositions and methods for treating cancer, including refractory cancer, such as refractory acute myeloid leukemia (AML) or ovarian cancer.
Disclosed is use of at least one compound in the manufacture of a medicament for treating a disorder associated with elevated TXNIP or elevated glucagon in a mammal, wherein the at least one compound has a structure represented by a formula selected from the group consisting of: , and
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
The present disclosure is concerned with dipeptide analogs that are capable of inhibiting TGF-ß and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, methods for immunotherapy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07K 5/068 - Dipeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p.ex. Lys, Arg
The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-ß and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
19.
BIOMARKERS AND METHODS FOR ASSESSING MYOCARDIAL INFARCTION AND SERIOUS INFECTION RISK IN RHEUMATOID ARTHRITIS PATIENTS
Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
20.
LACTATE DEHYDROGENASE A (LDHA) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting epression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Zolotukhin, Sergei
Boye, Sanford L.
Boye, Shannon E.
Marsic, Damien
Gamlin, Paul D.
Abrégé
Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p.ex. des bactéries ou des cellules animales; Bibliothèques contenues ou présentées dans des vecteurs, p.ex. des plasmides; Bibliothèques contenant uniquement des micro-organismes ou des vecteurs
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Zolotukhin, Sergei
Boye, Sanford L.
Boye, Shannon E.
Marsic, Damien
Gamlin, Paul D.
Abrégé
ABSTRACT Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells. Date Recue/Date Received 2021-04-12
A .GAMMA..DELTA.T cell including at least one vector, the at least one vector directing the expression of a chimeric antigen receptor (CAR) and a survival factor, wherein the CAR includes an extracellular domain including and a transmembrane domain, wherein the survival factor is a polypeptide that confers resistance to a chemotherapeutic agent; and wherein die cell expresses a stress-induced antigen receptor, wherein die stress-induced antigen receptor is the NKG2D receptor. A pharmaceutical composition including said .GAMMA..DELTA.T cell and a pharmaceutically acceptable carrier. Use of said pharmaceutical composition, wherein the composition is for administration concurrently with the chemotherapeutic agent, or after administration of the chemotherapeutic agent, or any combination thereof.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
The present embodiments provide compositions and methods related to novel recombinant protein immunogens, comprising specific portions of alpha helical domains (aHD) and proline rich regions (PRD) of pneumococcal surface protein A (PspA), which portions are linked to provide aHD-PRD constructs. The aHD and PRD proteins constituting the aHD-PRD constructs are selected to maximize cross-reactivity and provide protection against a broad spectrum of pneumococcal serotypes. Immunogenic compositions, including vaccines, comprising at least one aHD PRD construct may also include a non-linked aHD portion. Also provided are recombinant nucleic acid molecules that encode aHD-PRD constructs, vectors and recombinant host cells containing such molecules, aHD-PRD expression products, use of such nucleic acid molecules to express aHD-PRD constructs by recombinant techniques, and use of the expression products to elicit an immune or protective response against pneumococcal disease in a suitable host.
C07K 14/315 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptococcus (G), p.ex. Enterocoques
The present invention provides compositions and methods for combination therapy comprising administering to a patient in need thereof, drug-resistant immunotherapy, immune checkpoint inhibitors, and chemotherapy for the treatment of cancer.
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p.ex. chlorazanil, mélamine
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
VANDERBILT UNIVERSITY (USA)
THE UAB RESEARCH FOUNDATION (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventeur(s)
Maloney, David J.
Waterson, Alex Gregory
Bantukallu, Ganesha Rai
Brimacombe, Kyle Ryan
Christov, Plamen
Dang, Chi V.
Darley-Usmar, Victor M.
Hall, Matthew
Hu, Xin
Jadhav, Ajit
Jana, Somnath
Kim, Kwangho
Moore, William J.
Mott, Brian T.
Neckers, Leonard M.
Simeonov, Anton
Sulikowski, Gary Allen
Urban, Daniel Jason
Yang, Shyh Ming
Abrégé
The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
27.
GENETICALLY-ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME
The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of ?d T cell expansion and aß T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
VANDERBILT UNIVERSITY (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Maloney, David J.
Jadhav, Ajit
Bantukallu, Ganesha Rai
Brimacombe, Kyle Ryan
Mott, Bryan T.
Yang, Shyh Ming
Urban, Daniel Jason
Hu, Xin
Simeonov, Anton
Kouznetsova, Jennifer L.
Waterson, Alex Gregory
Sulikowsky, Gary Allen
Kim, Kwangho
Christov, Plamen
Jana, Somnath
Darley-Usmar, Victor M.
Moore, William J.
Neckers, Leonard M.
Dang, Chi V.
Abrégé
Provided is a compound of formula (I) in which Arl, Rl, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/ or lactate dehydrogenase B (LDHB) activity in a cell.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
VANDERBILT UNIVERSITY (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Maloney, David J.
Jadhav, Ajit
Bantukallu, Ganesha Rai
Brimacombe, Kyle Ryan
Mott, Bryan T.
Yang, Shyh Ming
Urban, Daniel Jason
Hu, Xin
Simeonov, Anton
Kouznetsova, Jennifer L.
Waterson, Alex Gregory
Sulikowski, Gary Allen
Kim, Kwangho
Christov, Plamen
Jana, Somnath
Darley-Usmar, Victor M.
Neckers, Leonard M.
Moore, William J.
Abrégé
Provided is a compound of formula (I)[Formula (I) should be inserted here], in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/ or lactate dehydrogenase B (LDHB) activity in a cell.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
Discosed are synthetic apolipoprotein E-mimicking peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for reducing plasma cholesterol; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating lipid and metabolic disorders using the disclosed synthetic apolipoprotein E-mimicking peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/483 - Analyse physique de matériau biologique
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
In one embodiment, a self-restoring crash cushion including multiple diaphragms spaced along a length direction of the cushion, an elongated track adapted to be anchored to the ground that extends along the length direction under the cushion, the diaphragms being mounted to the track in a manner in which they can slide along the track when impacted by a moving vehicle or when the cushion is being restored, and means for dissipating energy of the moving vehicle.
E01F 15/14 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules spécialement adaptées pour une protection localisée, p.ex. pour piles de ponts, pour îlots de circulation
E01F 15/00 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules
In one embodiment, an energy absorbing system includes a tube section having a distal end and an energy absorber mounted to the tube section and receiving its distal end, the energy absorber including a folding section and a compressing section inward, the folding section being adapted to fold opposed walls of the tube section and the compressing section being adapted to compress the tube section after it has been folded.
F16F 7/12 - Amortisseurs de vibrations; Amortisseurs de chocs utilisant une déformation plastique de ses organes
E01F 15/00 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules
E01F 15/04 - Barrières continues s'étendant le long des routes ou entre les voies de circulation constituées essentiellement de poutres longitudinales ou de bandes rigides
36.
SYSTEM AND METHOD FOR MANAGING SPATIOTEMPORAL UNCERTAINTY
Provided herein are methods and systems for managing spatiotemporal uncertainty in image processing. A method can comprise determining motion from a first image to a second image, determining a latency value, determining a precision value, generating an uncertainty element based upon the motion, the latency value, and the precision value, and rendering the uncertainty element.
H04N 19/139 - Analyse des vecteurs de mouvement, p.ex. leur amplitude, leur direction, leur variance ou leur précision
H04N 19/17 - Procédés ou dispositions pour le codage, le décodage, la compression ou la décompression de signaux vidéo numériques utilisant le codage adaptatif caractérisés par l’unité de codage, c. à d. la partie structurelle ou sémantique du signal vidéo étant l’objet ou le sujet du codage adaptatif l’unité étant une zone de l'image, p.ex. un objet
A method for identifying phishing websites and illustrating the provenance of each website through the structural components that compose the websites. The method includes identifying newly observed phishing websites and using the method as a distance metric for clustering phishing websites. Varying the threshold value within method demonstrates the potential capability for phishing investigators to identify the source of many phishing websites as well as individual phishers.
G06F 21/00 - Dispositions de sécurité pour protéger les calculateurs, leurs composants, les programmes ou les données contre une activité non autorisée
38.
ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCLEOSIDE HYDROLASE PRODRUG RELATED APPLICATIONS
The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Sanders, Paul W.
Abrégé
Provided herein are polypeptides comprising or consisting essentially of a QSYDNTLSGSYVF (SEQ ID NO:1) or LSADSSGSYLYVF (SEQ ID NO:2) amino acid sequence. Also provided herein are methods of treating or preventing cast nephropathy in a subject. The methods comprise identifying a subject with or at risk of developing cast nephropathy and administering to the subject any of the polypeptides disclosed herein.
In some embodiments, a transport chair includes a base frame, a seat assembly pivotally mounted to the base, and a footrest assembly pivotally mounted to the base frame, the footrest assembly being associated with the seat assembly so as to pivot in unison with the seat assembly until the seat assembly is pivoted forward to an extent at which the footrest assembly contacts the floor or ground, at which point the footrest assembly does not pivot further upon further forward pivoting of the seat assembly.
Disclosed herein are peptide amphiphiles for use in producing a natural endothelium mimicking nanomatrix. The disclosed natural endothelium mimicking nanomatrix can be used to coat medical devices such as vascular stents to promote endothelializaiton and inhibit restenosis and thrombosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminée; Leurs dérivés
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild- type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G01N 33/483 - Analyse physique de matériau biologique
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p.ex. par magnétisme, par des ondes sonores
ABSTRACT Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild- type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression. Date Recue/Date Received 2020-09-04
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G01N 33/483 - Analyse physique de matériau biologique
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p.ex. par magnétisme, par des ondes sonores
The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photobleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods.
A61B 3/02 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure subjective, c. à d. appareils de d’examen nécessitant la participation active du patient
A61B 3/06 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure subjective, c. à d. appareils de d’examen nécessitant la participation active du patient pour examen de vision des couleurs
47.
METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE LYMPHOCYTE RECEPTORS OF DEFINED ANTIGEN SPECIFICITY
Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/12 - Gènes codant pour des protéines animales
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
48.
MID-IR LASER INSTRUMENT FOR ANALYZING A GASEOUS SAMPLE AND METHOD FOR USING THE SAME
An optical nose for detecting the presence of molecular contaminants in gaseous samples utilizes a tunable seed laser output in conjunction with a pulsed reference laser output to generate a mid-range IR laser output in the 2 to 20 micrometer range for use as a discriminating light source in a photo- acoustic gas analyzer.
H01S 3/10 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p.ex. commutation, ouverture de porte, modulation ou démodulation
49.
STREPTOCOCCUS PNEUMONIA HAVING A CAPSULAR POLYSACCHARIDE REPEATING UNIT {>2)GLUCOSE 1(1>3) GLUCOSE 2 (1>3) RHAMNOSE (1>3)RIBITOL (5>PHOSPHATE}
Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {.fwdarw.2) glucose 1 (1.fwdarw.3) glucose 2 (1.fwdarw.3) rhamnose (1.fwdarw.3) ribitol (5.fwdarw.phosphate}. This new serotype may be included in pneumococcal vaccines.
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
50.
PROCESS FOR METABOLIC CONTROL AND HIGH SOLUTE CLEARANCE AND SOLUTIONS FOR USE THEREIN
The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described herein offers significant advantages over the prior art solutions used in CRRT. The present disclosure describes superior metabolic and electrolyte control and significantly increased dialyzer patency in: (a) 24 intensive care unit (ICU) patients with ARF using a 0.67% trisodium citrate replacement fluid solution, and (b) 32 ICU patients with ARF using a 0.5% trisodium citrate replacement fluid solution. Both groups were treated with Bicarbonate-25 dialysate and achieved effluent rates of 35 mL/kg/hr.
brevets
